Kelby Sunarto, APRN
Family · Oklahoma City, OKNPI 1740700152
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Teleflex LLC at 32.7% of the total. Reporting peaked in 2022 at $3,787 and has fallen 56.0% since, to $1,665 in 2025. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $43.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$3K
- Axonics, Inc.$2K
- Medtronic$1K
- Boston Scientific$605
- Astellas Pharma US Inc$570
- Antares Pharma, Inc.$277
- plus $2K from 25 others
What the payments were for
- Travel & lodging$3,69338%
- Food & beverage$5,80460%
- Education$2262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 25 | $3,178 |
| Axonics, Inc. | 22 | $2,474 |
| Medtronic | 58 | $1,089 |
| Boston Scientific | 11 | $605 |
| Astellas Pharma US Inc | 20 | $570 |
| Antares Pharma, Inc. | 9 | $277 |
| Sumitomo Pharma America, Inc. | 12 | $213 |
| Endo USA, Inc. | 3 | $175 |
| Rochester Medical Corporation | 6 | $155 |
| Urogen Pharma, Inc. | 8 | $148 |
| Pfizer | 9 | $140 |
| Coloplast | 6 | $113 |
| Ferring Pharmaceuticals Inc. | 3 | $66 |
| Novartis | 2 | $62 |
| Myriad Genetic Laboratories, Inc. | 3 | $59 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| Tolmar, Inc. | 3 | $45 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $43 |
| Vertex | 2 | $37 |
| AbbVie | 2 | $35 |
| Millicent US Inc | 2 | $32 |
| GSK | 2 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Photocure Inc | 1 | $23 |
| Bayer | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Scynexis, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| 180 Medical, Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,722 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 498 | $429,061 |
| GemtesaVibegron | 123 | $93,216 |
| PremarinEstrogens, Conjugated | 39 | $16,913 |
| Methenamine Hippurate | 150 | $14,921 |
| Estradiol | 247 | $14,765 |
| Tamsulosin Hcl | 657 | $11,084 |
| Trospium Chloride | 113 | $10,632 |
| Trospium Chloride ErTrospium Chloride | 25 | $5,459 |
| Finasteride | 324 | $4,397 |
| Solifenacin Succinate | 74 | $3,891 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 129 | $2,816 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 21 | $2,809 |
| Oxybutynin Chloride ErOxybutynin Chloride | 122 | $2,092 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,949 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 67 | $1,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $570 | $429,061498 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $213 | $93,216123 claims |
| PfizerPremarin | $140 | $16,91339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.